An important update regarding registration and supply of Prochlorperazine - Prochlorperazine 3mg buccal tablets are now registered and listed on the schedule*

Max Health is pleased to announce a resolution to the recent issues with Prochlorperazine 3mg buccal tablets.  Max Health Director David Pascoe, said, “in order to address the needs of the New Zealand market, we have partnered with UK company Brown and Burk to achieve Medsafe registration of Prochlorperazine 3mg buccal tablets and ongoing supply for our local market.”  

Prochlorperazine is indicated for a variety of conditions including:

• the symptomatic treatment of vertigo due to Meniere's Disease, Labyrinthitis and other causes 

• nausea and vomiting from whatever cause and

• in the treatment of migraine1.

Max Health's prochlorperazine 3mg buccal tablets are now:

• Medsafe registered and

• listed on the pharmaceutical schedule*.

*A part-charge will apply

1. Prochlorperazine data sheet, December 2024, www.medsafe.govt.nz

Prochlorperazine maleate 3mg buccal tablets. 

Indications: Prochlorperazine maleate is indicated in adults & children >12 yrs: Symptomatic treatment of vertigo due to Meniere's Disease, Labyrinthitis and other causes; For nausea and vomiting from whatever cause; In the treatment of migraine.  

Warnings & Precautions: Use with caution in patients with stroke risk factors; myasthenia gravis; AIDS; hypotension; dementia; neuroleptic malignant syndrome; venous thromboembolism; QT prolongation & carbohydrate malabsorption disorders.   

Interactions: Alcohol, CNS depressants; antihypertensives; neuroleptics; anticoagulants; Anticonvulsants; lithium; desferrioxamine; levodopa; anti-arrhythmics, antidepressants, macrolide-antibiotics & other antipsychotics.  

Prochlorperazine maleate is a partially funded prescription only medicine. Please review the full Data Sheet before prescribing. Data sheets are available at www.medsafe.govt.nz . 

Distributed by Max Health Ltd, Auckland. Date of Preparation March 2025. MXH/NZ/PROCHLORPERAZINE/002.

NEW Product Launch - Stalevo® Tablets from Orion Pharma and Max Health

Max Health and Orion Pharma are proud to announce the launch of STALEVO® (levodopa, carbidopa and entacapone) tablets in New Zealand. Stalevo is a pioneering triple therapy for Parkinson's and is fully funded from 1 February 2025.

STALEVO combines levodopa, carbidopa, and entacapone in a single tablet, providing a convenient solution for patients not stabilised on traditional levodopa/dopa decarboxylase inhibitor treatment.

Stalevo details are as follows:

Stalevo levodopa/carbidopa/entacapone OneLink Code Pharmacode

Stalevo 50/12.5/200 1260191 2696533

Stalevo 100/25/200 1260192 2696541

Stalevo 150/37.5/200 1260193 2696568

Stalevo 200/50/200 1260194 2696576

As with all other Max Health products, Stalevo Tablets can be ordered from Onelink using this contact information.

Phone: 0800-70-80-60
Fax: 0800-26-69-60
Email: customerservices@onelink.co.nz

NEW Product Launch Modafinil 100mg Tablets from Max Health

Max Health is delighted to announce the launch of Modafinil Tablets in New Zealand. Modafinil 100mg Tablets are available now and will be listed in Section B and H of the PHARMAC Schedule effective from 1st December 2024, with Principal Supply Status commencing on 1st May 2025.  

In addition to this we’d like to draw your attention to new prescribing criteria for Modafinil announced today by PHARMAC.  From 1 December 2024, the renewal criteria will be removed from Modafinil tablets, making it easier for people who need this treatment to access it. 

So, this is good news on two fronts for patients receiving Modafinil treatment!

Max Health Modafinil 100mg Tablet details are as follows:

Name: Modafinil Tab
Strength: 100mg; 30 tablet blister pack
OneLink Code: 1194157
Pharmacode: 2690586
Price: POA

As with all other Max Health products, Modafinil 100mg Tablets can be ordered from Onelink via the following details.

Phone: 0800-70-80-60
Fax:      0800-26-69-60
Email:  customerservices@onelink.co.nz

Levocarnitine 500mg capsules- Schedule Listed from 1st September

Max Health’s Levocarnitine 500mg capsules are available and listed in the Pharmaceutical Schedule from Sept 1st 2024

Metabolics-brand Levocarnitine capsules are Australian made in a GMP accredited manufacturing facility.  Capsules are 500mg each and pack (pot) contains 300 caps. Both the capsule and content is vegetarian friendly and has a low carbohydrate content so may be useful for those requiring a ketogenic diet.

Details of Levocarnitine are as follows:  

Product:               Metabolics Levocarnitine 500mg Capsules
Manufacturer:      Reach Pharma, Australia
Pharmacode:       2683059
OneLink code      1165451                               
Schedule:             Listed from 1st September 2024

As with all Max Health products, Metabolics-brand Levocarnitine caps are available through OneLink.

Phone: 0800 70 80 60

Fax: 0800 26 69 60

Email: customerservices@onelink.co.nz
 

Modafinil Tablets – New Tender Listing – Section B and Section H

Max Health is pleased to announce the listing of Modafinil 100mg Tablets in Section B and H of the PHARMAC Schedule effective from the 1st November 2024. The product is supplied by our partner Chanelle Pharma based out of Ireland and has been awarded Principal Supply Status from the 1st May 2025.  

Modafinil 100mg Tablet details are as follows:

Name: Modafinil

Strength: Tab 100mg; 30 tablet blister pack.

Pharmacode: 2690586

Price: POA

As with all other Max Health products, Modafinil 100mg Tablets can be ordered from Onelink via the following details.

Phone: 0800 70 80 60

Fax: 0800 26 69 60

Email: customerservices@onelink.co.nz

Max Health Innovation Grant 2024 - ENTRIES OPEN

Do you have a great idea for improving patient care?

• Are you struggling to implement a new model of service due to lack of resources?

• Got the initiative but need the support?

• Would you like a complimentary registration to the New Zealand Hospital Pharmacy Association (NZHPA) Conference?

If the answer is yes, this grant could be for you!

Max Health, a small and innovative NZ based company, are proud to offer this $3000 prospective grant to support research and professional development in areas that align with the values of Max Health:

• Innovation in pharmacy practice

• Problem solving

• Exceeding customer expectations

The grant can be used to support service improvement initiatives, research projects, national or international study tours, preceptorships, international and local travel to relevant conferences.

Submit your proposal and you could be one of the finalists invited to pitch your idea to a panel of judges via Teams in September 2024. The winner will receive a complimentary registration to the 2024 NZHPA Conference in Dunedin, 23-24 November to present their winning idea.

Eligibility criteria

1. Applications must demonstrate innovation in pharmacy practice, problem solving or exceeding customer expectations.

2. Work can be current, prospective, or retrospective work (within the last 12 months) that you wish to develop further.

3. Applicants must be current ordinary members of the New Zealand Hospital Pharmacy Association (NZHPA).

Application Process

Complete the online application form by 5pm Friday 6 September 2024 via the NZHPA Website - HERE

If you have any questions please contact Lisa, NZHPA Administrator: nzhpa@nzhpa.org.nz 

Nicorandil Tablets – New Tender Listing – Section B and Section H

Max Health is delighted to announce the listing of Nicorandil 10mg and 20mg tablets in Section B and H of the PHARMAC Schedule effective from the 1st December 2023. The product is supplied by our partner Rivopharm based out of Switzerland and has been awarded Principal Supply Status from the 1st May 2024.

Nicorandil Tablet details are as follows:

Name: Nicorandil Oral Tablets

Strength: 10mg

Pharmacode: 2669242

Name: Nicorandil Oral Tablets

Strength: 20mg

Pharmacode: 2669250

As with all other Max Health products, Nicorandil tablets can be ordered from Onelink via the following details.

Phone: 0800 70 80 60

Fax: 0800 26 69 60

Email:

 customerservices@onelink.co.nz

Max Health Pharmacy Innovation Showcase Award 2023

Max Health is proud to be supporting the annual Max Health Pharmacy Innovation Showcase Award 2023 at the upcoming NZHPA Annual Conference held in Wellington this year.

- Do you have a great idea for improving patient care?
- Are you struggling to implement a new model of service due to lack of resources?
- Are you currently running something that needs a boost?
- Got the initiative, but need the support?

If the answer is yes, the Max Health Pharmacy Innovation Showcase Award 2023 could be for you.

Complete an Application for Max Health Award found on the NZHPA website at http://www.nzhpa.org.nz/

Max Health are proud to offer this award to support research and professional development of clinical pharmacists and technicians in areas that align with the values of Max Health:

• Innovation in pharmacy practice

• Problem solving

• Exceeding customer expectations

New Max Health team members - welcoming Lisa Chang and Leanne Carpendale

Max Health would like to extend a warm welcome to our newest team members, Lisa Chang and Leanne Carpendale.

LISA CHANG
Commercial Manager

Lisa joined Max Health in September 2022 after gaining over 10 years of pharmaceutical experience since starting her career initially as a NZ registered pharmacist at various Unichem and Life Pharmacies before moving into the pharmaceutical industry whilst completing a Masters in Bioscience Enterprise. Lisa brings a wealth of international pharmaceutical experience and networks through leading market expansion of innovative medicines into more than twenty markets across Asia, Northern America, UK and Europe whilst at AFT Pharmaceuticals. This experience developed her skills across the various functions of the pharmaceutical business. Lisa joined as Commercial Manager and manages our Key Supplier Accounts, Sales and Marketing of Promoted products and the National Tender process for the company.

In her free time, you can find Lisa enjoying walks with her family or outside growing cut- flowers in her garden.

LEANNE CARPENDALE
Office Administration and Logistics Co-ordinator

Leanne joined the Max Health team at the start of 2023. She brings with her a vast array of skills, experience, and wisdom to the Max Health team. Leanne previously worked for Janssen-Cilag for 23 years in a variety of marketing and administrative roles. At Max Health, Leanne provides support for Logistics functions. She also manages the Max Health office, handling a wide range of administrative duties.

Outside of Max Health Leanne is a Mother of two Teenage boys. Leanne spends a lot of her spare time at Auckland United Football Club, where she is Youth Chair, Grade Co-ordinator and the Manager of both her son’s teams.

2023 is off to a great start with our newest additions! Welcome to the Max Health team Lisa and Leanne.

Clinical pharmacist, Fiona McNabb wins Max Health Pharmacy Innovation Showcase Award 2022

Max Health is delighted to announce clinical pharmacist Fiona McNabb as the winner of the Max Health Pharmacy Innovation Showcase Award 2022. 

Fiona started Talking about Medicines as a passion project to help people better understand how and why their medicines work. Using simple drawings and a spoken ‘story’ her videos effectively communicate WHY medicines are useful for certain conditions, HOW they work and WHAT benefits you should expect to get from them. Anyone can access the Talking About Medicines videos free via the website.

With the Max Health Pharmacy Innovation Showcase Award funding, Fiona and her team are looking forward to producing te reo Māori translations of cardiac videos including ‘How the heart works.’

Max Health are proud to offer this award to support research and professional development of clinical pharmacists and technicians in areas that align with the values of Max Health:

• Innovation in pharmacy practice

• Problem solving

• Exceeding customer expectations

We look forward to meeting this year’s applicants at the NZHPA Annual Conference 2023.

Levomepromazine Injection – New Tender Listing – Section B and Section H

Max Health is pleased to announce the listing of Levomepromazine hydrochloride (Wockhardt) inj 25 mg per ml, 1 ml ampoule in Section B and H of the PHARMAC Schedule effective from the 1st November 2022. The product is supplied by our partner Wockhardt, based out of the UK and has been awarded Principal Supply Status from the 1st April 2023.

Levomepromazine Injection details are as follows:

Name: Levomepromazine hydrochloride injection

Strength: 25mg/1mL, 10 x 1mL ampoules

Onelink Code: PHAE76

Pharmacode: 2501902

Price: POA

As with all other Max Health products, Levomepromazine injection can be ordered from Onelink via the following details.

Phone: 0800 70 80 60

Fax: 0800 26 69 60

Email: customerservices@onelink.co.nz

Max Health and Hameln to launch Clindamycin 150mg/mL solution for injection into the New Zealand pharmaceutical market.

Max Health is pleased to announce the upcoming launch of Clindamycin-hameln, 150mg/mL solution for injection, the newest addition to Hameln Pharma’s growing product portfolio in New Zealand.

Clindamycin Injection has been awarded Principal Supply Status from the 1st August 2023 and will be available in New Zealand from the 12th February 2023 from Onelink. This recent announcement is a testament to the commitment of Max Health and Hameln in serving the wellbeing of patients through supply of high quality and reliable European products in New Zealand.

Clindamycin details are as follows:

Name: Clindamycin Injection

Strength: 150mg/mL, 4mL x 10

Onelink Code: PHZB72

Pharmacode: 2646595

Price: POA

As with all other Max Health products, Clindamycin can be ordered from Onelink via the following details.

Phone: 0800 70 80 60

Fax: 0800 26 69 60

Email: customerservices@onelink.co.nz

About Hameln Plus – Germany

The Hameln group, based in Hameln Germany has over 100 years of company history behind it, having been run by the same family for four generations. It produces an outstanding range of injectable anaesthetic and intensive medicine products, in a state of the art sterile facility. Products approved and marketed in NZ include Alfentanil, Cyclizine, Dexamethasone, Amiodarone, Naloxone, Neostigmine, Oxycodone, Dobutamine, Flumazenil and Rocuronium injections.

About Max Health

Established in 2008, Max Health™ is a New Zealand founded pharmaceutical company providing products and solutions to the New Zealand health care market. We distribute a wide variety of pharmaceutical products sourced from well established European pharmaceutical companies. We pride ourselves in providing high quality products with reliable local service.